Therapeutic Considerations in Metastatic HER2+ Breast Cancer | OncLive

Therapeutic Considerations in Metastatic HER2+ Breast Cancer

September 1, 2020

Join us to learn more about how the field in HER2+ breast cancer is evolving and hear direct from leading experts, Hope Rugo, MD and Sara Hurvitz, MD on Monday, September 21, 2020 at 8 PM PDT.

Exclusive for Southern California Breast Cancer Surgeons

Therapeutic Considerations in Metastatic HER2+ Breast Cancer

Date: Monday, September 21, 2020

Time: 8 PM - 9:30 PM PDT


Join us to learn more about how the field in HER2+ breast cancer is evolving and hear direct from leading experts, Hope Rugo, MD and Sara Hurvitz, MD.

The following objectives will be reviewed and discussed:

Review and evaluate data on recent therapeutic advances in metastatic HER2+ breast cancer

Discuss clinical challenges and areas of uncertainty faced when selecting later lines of therapy for patients with metastatic HER2+ breast cancer

Identify factors that influence treatment selection and planning for patients with metastatic HER2+ breast cancer

Speakers:

Hope Rugo, MD

Professor of Medicine Director, Breast Oncology and Clinical Trials Education UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, CA

Sara Hurvitz, MD

Professor of Medicine
UCLA
Hematology/Oncology
Los Angeles, CA


x